Pacira BioSciences (NASDAQ:PCRX) Stock Rating Lowered by Zacks Research

Pacira BioSciences (NASDAQ:PCRX) was downgraded by equities research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report issued on Monday, Zacks reports.

Other equities analysts have also issued research reports about the stock. Oppenheimer began coverage on shares of Pacira BioSciences in a report on Wednesday, September 23rd. They set an “outperform” rating and a $32.00 price target on the stock. Royal Bank Of Canada increased their target price on shares of Pacira BioSciences from $24.00 to $25.00 and gave the stock a “sector perform” rating in a research note on Wednesday, August 5th. Weiss Ratings cut shares of Pacira BioSciences from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, September 16th. Leerink Partners initiated coverage on Pacira BioSciences in a report on Wednesday, September 9th. They issued a “market perform” rating and a $28.00 price target on the stock. Finally, Needham & Company LLC raised their price objective on shares of Pacira BioSciences from $32.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $30.14.

Pacira BioSciences Trading Down 1.2%

Shares of PCRX stock opened at $24.76 on Monday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 3.94 and a current ratio of 5.04. Pacira BioSciences has a fifty-two week low of $18.80 and a fifty-two week high of $27.66. The company has a market cap of $986.93 million, a PE ratio of 70.74 and a beta of 0.25. The stock’s fifty day moving average price is $25.20 and its two-hundred day moving average price is $24.39.

Pacira BioSciences (NASDAQ:PCRX) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $0.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.08. The company had revenue of $192.40 million for the quarter, compared to analyst estimates of $191.06 million. Pacira BioSciences had a net margin of 1.96% and a return on equity of 9.68%. The firm’s revenue was up 6.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.74 EPS. Equities analysts predict that Pacira BioSciences will post 1.91 EPS for the current fiscal year.

Insider Buying and Selling at Pacira BioSciences

In other news, insider Jonathan Slonin sold 3,040 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $23.23, for a total value of $70,619.20. Following the sale, the insider owned 216,384 shares of the company’s stock, valued at $5,026,600.32. The trade was a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. purchased a new position in Pacira BioSciences during the 1st quarter valued at about $46,000. Global Retirement Partners LLC purchased a new stake in shares of Pacira BioSciences in the second quarter worth about $51,000. State of Wyoming purchased a new stake in shares of Pacira BioSciences in the second quarter worth about $78,000. PNC Financial Services Group Inc. boosted its position in shares of Pacira BioSciences by 15.1% in the first quarter. PNC Financial Services Group Inc. now owns 3,751 shares of the company’s stock valued at $85,000 after acquiring an additional 492 shares during the period. Finally, Keating Financial Advisory Services Inc. purchased a new position in Pacira BioSciences during the second quarter valued at approximately $110,000. Institutional investors own 99.73% of the company’s stock.

Trending Headlines about Pacira BioSciences

Here are the key news stories impacting Pacira BioSciences this week:

• Positive Sentiment: Pacira granted Molteni Farmaceutici exclusive rights to commercialize EXPAREL in the European Union and United Kingdom. The agreement expands access to Pacira’s opioid-sparing postsurgical pain treatment and supports management’s “5×30” growth strategy by extending the product’s international reach. Financial terms were not disclosed. Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL
• Positive Sentiment: Analysts tracked by American Banking News have a consensus price target of $30.14, above the current $24.76 level. That target indicates potential upside if Pacira executes on its commercial expansion and improves earnings growth. Pacira BioSciences Consensus Target Price
• Neutral Sentiment: Coverage of the Molteni transaction highlights an “undervalued” narrative, but investors will likely look for evidence that the European launch generates meaningful revenue and profitability before assigning greater value to the deal. Pacira BioSciences on Its Molteni Deal and the Undervalued Narrative
• Negative Sentiment: Zacks Research downgraded PCRX from “Hold” to “Strong Sell.” The downgrade is the clearest near-term negative catalyst and may raise concerns about valuation, earnings momentum, or execution despite the European partnership. Zacks Research Downgrades Pacira BioSciences to Strong Sell

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain-management products. The company’s portfolio is designed to help manage acute and chronic pain while reducing reliance on traditional opioid therapies.

Its principal product is EXPAREL, an extended-release formulation of bupivacaine used to provide postsurgical pain relief. Pacira also markets ZILRETTA, an extended-release corticosteroid injection for osteoarthritis-related knee pain, and the iovera° system, a handheld cryoanalgesia device intended to temporarily block peripheral nerves and provide targeted pain relief.

Originally known as Pacira Pharmaceuticals, the company adopted the name Pacira BioSciences in 2018 to reflect its broader focus on innovative therapies and technologies.